The Causes of NEURODEGENERATION
and How We Work to Limit Its Progress
WHAT IS NEURODEGENERATION
The buildup of neurotoxic proteins impede healthy axonal transport
with normal levels of AB, tau and αSYN.
with an increase in aggregating proteins
reduces neurotoxic proteins and improves brain chemistry
Our Solution to Reverse Neurodegeneration
ANVS401 is a small lipophilic molecule that is orally available and readily enters the brain as demonstrated by pharmacokinetic analyses showing brain concentrations approximately 6 to 8 times higher than plasma concentrations. ANVS401 has a unique mechanism of action in that it inhibited the translation and, therefore, the levels of several key neurotoxic proteins both in vitro and in vivo including APP, tau and αSYN.
Brain injuries and stresses lead to increases in neurotoxic proteins, impaired axonal transport and nerve cell death – neurodegenerative diseases
OUR MECHANISMS OF ACTION
A Three-Prong Attack on AD and PD
We believe ANVS401 is the only drug in development that targets multiple neurotoxic proteins. Attacking one improve axonal transport in DS, AD and PD. The multiple conditions we will target include;
We Are Dedicated to Reversing Debilitating Neurodegenerative Diseases
By targeting multiple neurotoxic proteins, ANVS401 resembles a combination therapy approach, with the added convenience of being a single drug with a single drug target. Therefore, we have worked to understand how ANVS401 is able to inhibit the translation of more than one neurotoxic protein.
2018 Teich AD APP
2018 Cleveland Clinic Talk
2014 Rockefeller University Talk
2012 US Patent 8,258,172 Dementia
2012 US 20120225922 Neurodegeneration Application
2010 US Patent 7,786,162 Methods for Treating Dementia
2009 US Patent 7,625,942 Down Syndrome
2006 US Patent 7,153,882 Pos Composition + Use
2002 US Patent 6,495,700 Process